Fixed-Dose Brimonidine-Timolol Eye Drops for Lower Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma and ocular hypertension using brimonidine and timolol require separate dosing, which can be cumbersome and increase adverse events, particularly in patients who need both medications.
Innovation Solution
A fixed dose combination of 0.1% w/v brimonidine tartrate and 0.68% w/v timolol maleate is formulated for topical ocular administration, reducing side effects and simplifying treatment administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If brimonidine and timolol are administered as separate monotherapies, then each medication can be optimized for its specific therapeutic effect, but treatment complexity increases and adverse events multiply
Solution Approach 1:
The patent combines brimonidine and timolol into a single fixed-dose combination ophthalmic solution, merging two separate medications into one formulation. This resolves the contradiction by maintaining the therapeutic efficacy of both drugs while simplifying administration to a single dose, thereby reducing treatment complexity without compromising reliability
2Reliability
If brimonidine and timolol are used concurrently as separate medications, then comprehensive therapeutic coverage is achieved, but the incidence of adverse events increases
Solution Approach 1:
By merging brimonidine and timolol into a single fixed-dose combination product, the patent reduces the number of separate administrations required. This approach maintains comprehensive therapeutic coverage while decreasing the incidence of adverse events such as allergic conjunctivitis, conjunctival folliculosis, and ocular stinging that occur with concurrent separate administration
3Adaptability or versatility
If separate dosing of brimonidine and timolol is required, then each drug can be dosed independently, but patient compliance decreases due to cumbersome administration
Solution Approach 1:
The fixed-dose combination formulation merges brimonidine and timolol into a single ophthalmic solution that can be administered together in one dose. This resolves the contradiction by improving administration convenience and patient compliance while maintaining the dosing flexibility needed for effective glaucoma management
Data Source
AI summary
Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.